-
Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates
Monday, December 31, 2018 - 10:00am | 1219Read More...After a strong 2017, biotech stocks are on track to end the year in the red despite a record 59 new molecular entity approvals, some noteworthy M&A deals and several breakthrough developments in drug discovery and research. Will the new year mark a reversal in fortunes for these firms? Here...
-
Here's Why Exelixis Is Trading Higher By 20%
Monday, October 16, 2017 - 9:16am | 380Read More...Shares of Exelixis, Inc. (NASDAQ: EXEL) were trading higher by 20 percent early Monday morning after the company announced an encouraging update for its CABOMETYX (cabozantinib) therapy for the treatment of patients with advanced hepatocellular carcinoma. The U.S. Food and Drug Administration has...
-
Exelixis Spikes Following Phase 3 Results Of Cabozantinib; EU Filing Planned For Early 2016
Tuesday, January 5, 2016 - 10:09am | 284Read More...Shares of Exelixis, Inc. (NASDAQ: EXEL) surged higher by more than 7 percent at $5.90 early Tuesday morning after the company announced positive results from its METEOR Phase 3 pivotal trial of cabozantinib. Exelixis' phase 3 pivotal trial involved 658 patients with renal cell carcinoma....
-
Exelixis Up 50% After Meteroric METEOR Results
Monday, July 20, 2015 - 9:38am | 287Read More...Shares of Exelixis, Inc. (NASDAQ: EXEL) were surging by more than 50 percent Monday after the company announced positive top-line results from METEOR in which the study met the primary endpoint of significantly improving progress-free survival. Exelixis's positive top-line results stem from...
-
Market Wrap For March 26: Markets Close Near Session Lows In Yet Another Volatile Trading Session
Wednesday, March 26, 2014 - 4:46pm | 2082Read More...U.S. stocks failed to rise in a choppy session which began the day in positive territory. Shares reversed and turned negative with technology stocks leading the way. The CBOE Volatility Index, also known as the "fear index" rose 3.9 percent to 14.57 despite economic data released today coming...
